35 /100
MEDIUM RISK
Score updated Jul 13, 2026

CTMX — CytomX Therapeutics, Inc. Dilution Risk Tracker

Track CTMX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track CTMX — Get alerts when the score changes →

As of July 13, 2026, CytomX Therapeutics, Inc. (CTMX) has a DilutionWatch DilutionScore of 35/100, rated MEDIUM dilution risk. CytomX Therapeutics, Inc. has a market capitalization of $783.73M, 217.70M shares outstanding, 183 institutional holders tracked. Key dilution vectors include 81.6K outstanding warrants, approximately 20 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
25
📊 Float Risk
7
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for CTMX.
🔔 Track CTMX — Get forecast alerts →

💹 Market Data

Market Cap$783.73M
Shares Outstanding217.70M
Float186.26M
Cash$106.32M
Debt$2.99M
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 47.5% shares (2026Q1 vs prior)
183 institutional holders · 222.39M shares
#1 FMR LLC 31.96M shares
#2 PERCEPTIVE ADVISORS LLC 20.20M shares
#3 VANGUARD CAPITAL MANAGEMENT LLC 17.47M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest35.57M
Days to Cover4.3
% of Float19.1%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Mar 31, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for CTMX Shareholders

CytomX Therapeutics, Inc. (CTMX) has a DilutionScore of 35/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 13, 2026.

DilutionWatch's EDGAR monitoring for CTMX shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for CTMX in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for CTMX alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track CTMX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking CTMX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for CTMX
📊 CTMX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 CTMX Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.